呼吸道病毒疫苗市场报告：2031 年趋势、预测与竞争分析

全球呼吸道病毒疫苗市场前景光明，在医生办公室、医院、诊所以及药局和零售市场都存在机会。预计到 2031 年全球呼吸道病毒疫苗市场规模将达到 145 亿美元，2025 年至 2031 年的复合年增长率为 7.4%。该市场的主要驱动因素是呼吸道病毒感染率的上升、人们对疫苗益处的认识不断提高以及政府为加快疫苗开发和分发而增加的支出。

• Lucintel 预测，灭活疫苗（可刺激强烈且持续的免疫反应）将在预测期内成为疫苗类型中成长率最高的。
• 在最终用途类别中，医院预计在预测期内将经历最高的成长。
• 根据地区划分，由于强大的医疗保健基础设施和政府资金，预计北美将在预测期内实现最高成长。

呼吸道病毒疫苗市场的策略性成长机会

受疫苗技术进步、需求成长和公共卫生重点转变的推动，呼吸道病毒疫苗市场在关键应用领域提供了几个独特的策略成长机会。

• 联合疫苗：开发预防多种呼吸道病毒的联合疫苗代表着巨大的成长机会。这种方法将简化疫苗接种时间表并提高整体疫苗接种率。
• mRNA 疫苗技术：利用 mRNA 技术研发呼吸道病毒疫苗具有成长潜力。它的灵活性和快速开发的能力使其在应对新出现的呼吸威胁方面具有重要价值。
• 通用疫苗：投资通用呼吸道病毒疫苗的研究可以帮助推动市场向前发展。这些疫苗提供了广泛的保护，并可能减少对多种疫苗的需求。
• 先进的接种方法：探索接种疫苗的新方法，如滴鼻剂和微针贴片，是一个不断发展的领域。这些将改善疫苗的给药方式和患者接受方式。
• 扩大市场进入：改善服务不足和新兴市场的疫苗取得管道是扩张的重要机会。加强分销网络和本地生产有助于填补疫苗供应和覆盖范围的空白。

这些因素正在刺激呼吸道病毒疫苗市场的创新，扩大覆盖范围并改善疫苗的可及性。这些对于有效应对呼吸道病毒爆发并改善全球卫生状况尤其重要。

呼吸道病毒疫苗市场驱动因素与挑战

技术进步、经济决定因素和监管问题等各种因素推动或阻碍了呼吸道病毒疫苗市场的发展。了解这些因素对于市场发展至关重要。

推动呼吸道病毒疫苗市场发展的因素包括：

• 技术进步：技术进步：mRNA 疫苗和联合疫苗等疫苗技术的创新将推动市场成长。这些进展将提高针对新病毒的疫苗的有效性、安全性和灵活性。
• 疫苗需求增加：呼吸道病毒的激增，加上持续的公共卫生宣传活动，刺激了对疫苗的需求。因此，对疫苗研发和生产的投资正在增加。
• 政府支持：政府的支持政策和对潜在通路研究的资金是主要驱动因素。政府倡议将促进疫苗的可及性并支持公共卫生目标。
• 扩大疫苗接种机会：改进的分发系统和提高的疫苗生产能力正在扩大服务不足社区的疫苗接种机会。这将消除地区差异，确保更多人能够享受疫苗接种计划。
• 研究与发展 (R&D)：持续的研究与开发活动对于疫苗技术和投放方法的创新至关重要。如果没有这些研究和开发，就不可能开发出新的疫苗或改进现有的疫苗。

呼吸道病毒疫苗市场面临的挑战包括：

• 监管障碍：满足核准疫苗所需的复杂监管要求非常困难。遵守国际标准会使流程复杂化并影响市场准入。
• 高成本：开发和生产疫苗的高成本可能会影响疫苗的可负担性。这一问题在疫苗供应有限的资源匮乏的国家尤其严重。
• 疫苗犹豫：消除疫苗犹豫和解决错误讯息有助于提高疫苗接种率。公众教育宣传活动对于消除接受疫苗的障碍至关重要。

这些驱动因素和挑战将对呼吸道病毒疫苗市场的创新、取得和公共卫生工作产生重大影响。解决这些因素可以改善疫苗的开发、分发和整体人口健康。

目录

第一章执行摘要

2. 全球呼吸道病毒疫苗市场：市场动态

• 简介、背景和分类
• 供应链
• 产业驱动因素与挑战

第 3 章 市场趋势与预测分析（2019-2031）

• 宏观经济趋势（2019-2024）与预测（2025-2031）
• 全球呼吸道病毒疫苗市场趋势（2019-2024 年）及预测（2025-2031 年）
• 全球呼吸道病毒疫苗市场（按类型）
  • 惰性/灭菌
  • 减毒活体
  • 重组
• 全球呼吸道病毒疫苗市场（依给药途径划分）
  • 肌肉注射
  • 鼻内
  • 皮下
• 全球呼吸道病毒疫苗市场（依适应症划分）
  • 流感
  • 麻疹
  • 腮腺炎和德国德国麻疹
  • 新冠病毒
• 全球呼吸道病毒疫苗市场（依最终用途划分）
  • 实践者
  • 医院
  • 诊所
  • 药局/商店
  • 其他的

第 4 章区域市场趋势与预测分析（2019-2031 年）

• 全球呼吸道病毒疫苗市场（按地区）
• 北美呼吸道病毒疫苗市场
• 欧洲呼吸道病毒疫苗市场
• 亚太呼吸道病毒疫苗市场
• 世界其他地区呼吸道病毒疫苗市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 全球呼吸道病毒疫苗市场成长机会（按类型）
  • 全球呼吸道病毒疫苗市场按给药途径分類的成长机会
  • 全球呼吸道病毒疫苗市场成长机会（依适应症划分）
  • 全球呼吸道病毒疫苗市场成长机会（依最终用途划分）
  • 全球呼吸道病毒疫苗市场成长机会（按地区）
• 全球呼吸道病毒疫苗市场的新趋势
• 战略分析
  • 新产品开发
  • 全球呼吸道病毒疫苗市场产能扩张
  • 全球呼吸道病毒疫苗市场的企业合併
  • 认证和许可

第七章主要企业简介

• Sanofi
• AstraZeneca
• Merck
• GlaxoSmithKline
• Serum Institute of India
• Moderna
• Bavarian Nordic

The future of the global respiratory virus vaccine market looks promising with opportunities in the physician office, hospital, clinic, and pharmacy/store markets. The global respiratory virus vaccine market is expected to reach an estimated $14.5 billion by 2031 with a CAGR of 7.4% from 2025 to 2031. The major drivers for this market are the rising rate of respiratory viral infections, growing awareness of the benefits of vaccines, and increasing government spending to fast-track the development of vaccines and ensure widespread access.

• Lucintel forecasts that, within the type category, inactivated/killed is expected to witness the highest growth over the forecast period due to their ability to stimulate a powerful and enduring immune response.
• Within the end-use category, the hospital is expected to witness the highest growth over the forecast period.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to its strong healthcare infrastructure and government funding.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Respiratory Virus Vaccine Market

The market for vaccines against respiratory viruses is transforming due to several key trends driven by technological advancements and changes in public health demands. These developments have defined the future of preventing respiratory viruses.

• Combination Vaccines: More attention is now being directed toward the development of vaccines that can protect against multiple respiratory infections, such as flu, COVID-19, and RSV. The purpose of combination vaccines is to simplify vaccination schedules and increase compliance.
• mRNA Technology: mRNA technology is not only meant for COVID-19 vaccinations. Researchers are also investigating its potential application in developing vaccines targeting different respiratory viral diseases, thus offering swift development and adaptability to new strains.
• Universal Respiratory Virus Vaccines: Attempts are being made to design universal vaccines that can offer broad protection against many kinds of respiratory viruses. By reducing the need for multiple shots, these universal vaccines can improve overall health outcomes in communities.
• Enhanced Delivery Methods: Research is being conducted on utilizing nasal sprays and microneedle patches, among other delivery methods, aiming to improve ease of administration as well as patient acceptance. These methods aim to increase vaccination rates and accessibility.
• Global Collaboration: Faster development and distribution of vaccines against respiratory viruses have been facilitated through increased international collaboration. Global partnerships seek to share research findings, resources, and distribution networks that better position everyone involved in addressing respiratory infections globally.

These trends focus on improving vaccine technology, broadening protection coverage, and enhancing delivery mechanisms, thereby altering the landscape of the respiratory virus vaccine market. They are necessary for tackling emerging threats from viruses causing respiratory illnesses while also positively influencing overall community well-being.

Recent Developments in the Respiratory Virus Vaccine Market

Advancements in the respiratory virus vaccine market are characterized by significant milestones involving the adoption of new technologies and approaches to enhance the effectiveness and accessibility of vaccines. Recent advancements have focused on increasing protection and managing emerging viral threats.

• Combination Vaccine Development: Ongoing efforts are aimed at developing combination vaccines that address influenza, COVID-19, and other respiratory viruses. The main aim of these vaccines is to simplify vaccination schedules and enhance overall immunity.
• Universal Vaccine Research: Progress is being made in research aimed at producing universal vaccines that can protect against various respiratory viruses. Such vaccines could lessen the need for multiple shots and offer more complete protection.
• Improved Vaccine Delivery: Innovations are being made regarding how vaccines will be administered, such as nasal sprays and microneedle patches. These methods seek to improve vaccine compliance among patients while ensuring better delivery procedures.
• Increased Production Capacity: Scaling up production capacity for vaccines, particularly in emerging markets, is critical in meeting growing demand and achieving equal distribution of vaccines.

These developments significantly influence the respiratory virus vaccine market through technological improvements, better delivery options, and increased manufacturing capacities, which are essential for improving global responses to viral threats to public health.

Strategic Growth Opportunities for Respiratory Virus Vaccine Market

The respiratory virus vaccine market distinctly offers several strategic growth opportunities across important applications, driven by advancements in vaccine technology, increasing demand, and shifting public health priorities.

• Combination Vaccines: Developing combination vaccines that protect against numerous respiratory viruses creates a significant growth opportunity. Streamlining immunization schedules through this approach improves overall vaccine uptake.
• mRNA Vaccine Technology: Utilizing mRNA technology for respiratory virus vaccines has growth potential. It is valuable for addressing emerging respiratory threats due to its flexibility and quick development capabilities.
• Universal Vaccines: Investing in universal respiratory virus vaccine research can propel the market forward. These vaccines could provide broad protection and reduce the need for multiple vaccines.
• Advanced Delivery Methods: Exploring new approaches to delivering vaccinations, including nasal sprays and microneedle patches, represents areas of growth. These will improve how the vaccine is administered and how it is accepted by patients.
• Expanded Market Access: Improving access to vaccines in underserved and emerging markets is a major opportunity for expansion. Enhanced distribution networks and local production can bridge gaps related to vaccine availability and coverage.

These factors are shaping the respiratory virus vaccine market by spurring innovation and extending coverage while making vaccines easily accessible to users. They are particularly essential in improving global health performance while effectively responding to respiratory virus incidences.

Respiratory Virus Vaccine Market Driver and Challenges

Various factors drive or hinder the respiratory virus vaccine market, including technological advancements, economic determinants, and regulatory issues. Understanding these components is critical for market development.

The factors responsible for driving the respiratory virus vaccine market include:

• Technological Advancements: Innovation in vaccine technology, such as mRNA and combination vaccines, boosts market growth. These advancements enhance the efficacy, safety, and flexibility of vaccines against new strains of viruses.
• Increased Demand for Vaccines: The surging prevalence of respiratory viruses, coupled with ongoing public health campaigns, stimulates demand for vaccines. This has resulted in increased investments in vaccine development and production.
• Government Support: Supportive government policies and financing for research on potential distribution channels are key drivers. Government initiatives promote the accessibility of vaccines and support public health goals.
• Expanded Vaccine Access: Better distribution systems and increased vaccine manufacturing capacity have expanded access to underserved areas. This helps to bridge gaps between communities while ensuring that more people are covered by immunization programs.
• Research and Development (R&D): Continuous R&D activities are crucial for innovations in vaccine technology and delivery methods. Without this kind of research, no new vaccines can be developed or improvements made to existing ones.

Challenges in the respiratory virus vaccine market include:

• Regulatory Hurdles: Navigating complex regulatory requirements for vaccine approval may be challenging. Conforming to international standards complicates the process and affects market entry.
• High Costs: Affordability could be hampered by high costs associated with developing and producing vaccines. This problem is particularly relevant in low-resource countries where vaccine availability is limited.
• Vaccine Hesitancy: Combatting hesitancy toward vaccination and addressing misinformation can help raise vaccination rates. Public education campaigns are essential to eliminate barriers to vaccine acceptance.

These drivers and challenges significantly impact innovation, access, and public health efforts in the respiratory virus vaccine market. By addressing these factors, it is possible to improve vaccine development, distribution, and the overall health status of the population.

List of Respiratory Virus Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies respiratory virus vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the respiratory virus vaccine companies profiled in this report include-

• Sanofi
• AstraZeneca
• Merck
• GlaxoSmithKline
• Serum Institute of India
• Moderna
• Bavarian Nordic

Respiratory Virus Vaccine by Segment

The study includes a forecast for the global respiratory virus vaccine market by type, route of administration, indication, end use, and region.

Respiratory Virus Vaccine Market by Type [Analysis by Value from 2019 to 2031]:

• Inactivated/Killed
• Live-Attenuated
• Recombinant

Respiratory Virus Vaccine Market by Route of Administration [Analysis by Value from 2019 to 2031]:

• Intramuscular
• Intranasal
• Subcutaneous

Respiratory Virus Vaccine Market by Indication [Analysis by Value from 2019 to 2031]:

• Influenza
• Measles
• Mumps & Rubella
• Coronavirus

Respiratory Virus Vaccine Market by End Use [Analysis by Value from 2019 to 2031]:

• Physician Offices
• Hospitals
• Clinics
• Pharmacies/Stores
• Others

Respiratory Virus Vaccine Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Respiratory Virus Vaccine Market

The market for respiratory virus vaccines is experiencing significant advancements driven by new pathogens, technologies, and changing public health needs. Improvements in the United States, China, Germany, India, and Japan indicate worldwide efforts toward better vaccine efficacy and availability against respiratory viral threats.

• U.S.: Updated vaccines against various respiratory viruses, including novel variants of influenza and RSV, have recently been approved in the U.S. The focus is on developing combined vaccines that work against different pathogens simultaneously to make immunization schedules more efficient.
• China: To curb the increasing number of respiratory virus infections, China's respiratory virus vaccine portfolio is advancing with innovative options for COVID-19 and influenza. Broader immunity coverage through a variety of strains is also a focus, while accessibility in urban cities and rural areas has been optimized.
• Germany: Germany is investing in next-generation respiratory virus vaccines, which include those with improved efficacy against seasonal flu and emerging respiratory viruses. Additionally, investment is directed toward mRNA vaccine technology for wider applications.
• India: The country is beginning to increase production capacity for respiratory virus vaccines, addressing the rising demand for COVID-19 and seasonal flu vaccines. Public health campaigns are being intensified to improve vaccination coverage in underserved regions.
• Japan: Advanced vaccinations offering prolonged protection and minimal side effects are currently being developed in Japan. Equally important are studies pursuing non-injectable administration modes for increased acceptance and convenience for the population.

Features of the Global Respiratory Virus Vaccine Market

Market Size Estimates: Respiratory virus vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Respiratory virus vaccine market size by various segments, such as by type, route of administration, indication, end use, and region in terms of ($B).

Regional Analysis: Respiratory virus vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, route of administrations, indications, end uses, and regions for the respiratory virus vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the respiratory virus vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the respiratory virus vaccine market by type (inactivated/killed, live-attenuated, and recombinant), route of administration (intramuscular, intranasal, and subcutaneous), indication (influenza, measles, mumps & rubella, and coronavirus), end use (physician offices, hospitals, clinics, pharmacies/stores, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Respiratory Virus Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Respiratory Virus Vaccine Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Respiratory Virus Vaccine Market by Type
  • 3.3.1: Inactivated/Killed
  • 3.3.2: Live-Attenuated
  • 3.3.3: Recombinant
• 3.4: Global Respiratory Virus Vaccine Market by Route of Administration
  • 3.4.1: Intramuscular
  • 3.4.2: Intranasal
  • 3.4.3: Subcutaneous
• 3.5: Global Respiratory Virus Vaccine Market by Indication
  • 3.5.1: Influenza
  • 3.5.2: Measles
  • 3.5.3: Mumps & Rubella
  • 3.5.4: Coronavirus
• 3.6: Global Respiratory Virus Vaccine Market by End Use
  • 3.6.1: Physician Offices
  • 3.6.2: Hospitals
  • 3.6.3: Clinics
  • 3.6.4: Pharmacies/Stores
  • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Respiratory Virus Vaccine Market by Region
• 4.2: North American Respiratory Virus Vaccine Market
  • 4.2.1: North American Market by Type: Inactivated/Killed, Live-Attenuated, and Recombinant
  • 4.2.2: North American Market by End Use: Physician Offices, Hospitals, Clinics, Pharmacies/Stores, and Others
• 4.3: European Respiratory Virus Vaccine Market
  • 4.3.1: European Market by Type: Inactivated/Killed, Live-Attenuated, and Recombinant
  • 4.3.2: European Market by End Use: Physician Offices, Hospitals, Clinics, Pharmacies/Stores, and Others
• 4.4: APAC Respiratory Virus Vaccine Market
  • 4.4.1: APAC Market by Type: Inactivated/Killed, Live-Attenuated, and Recombinant
  • 4.4.2: APAC Market by End Use: Physician Offices, Hospitals, Clinics, Pharmacies/Stores, and Others
• 4.5: ROW Respiratory Virus Vaccine Market
  • 4.5.1: ROW Market by Type: Inactivated/Killed, Live-Attenuated, and Recombinant
  • 4.5.2: ROW Market by End Use: Physician Offices, Hospitals, Clinics, Pharmacies/Stores, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Respiratory Virus Vaccine Market by Type
  • 6.1.2: Growth Opportunities for the Global Respiratory Virus Vaccine Market by Route of Administration
  • 6.1.3: Growth Opportunities for the Global Respiratory Virus Vaccine Market by Indication
  • 6.1.4: Growth Opportunities for the Global Respiratory Virus Vaccine Market by End Use
  • 6.1.5: Growth Opportunities for the Global Respiratory Virus Vaccine Market by Region
• 6.2: Emerging Trends in the Global Respiratory Virus Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Respiratory Virus Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Respiratory Virus Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Sanofi
• 7.2: AstraZeneca
• 7.3: Merck
• 7.4: GlaxoSmithKline
• 7.5: Serum Institute of India
• 7.6: Moderna
• 7.7: Bavarian Nordic